Novo Nordisk announced in a news release Monday that it had pulled its semaglutide, Wegovy, from Hims & Hers, alleging it was selling compounded drugs as "personalized" versions to customers
They are stacking it with other supplements, combining it with dietary changes, or in some cases, taking it alongside GLP-1 medications
Not officially a weight loss drug, semaglutide injections like Ozempic and Wegovy have been proven to be an effective anti obesity treatment in non diabetic adults who are overweight or obese
More broadly, any product marketed for weight loss may create delays in proper diagnosis or treatment if a person relies on it instead of seeking medical care for obesity, insulin resistance, or diabetes
utilized claims records extracted from the National Health Insurance Research Database (NHIRD) and suggested that patients with diabetes who underwent GLP-1 RA therapy experienced a significant reduction in the risk of anxiety 20
FeelGood's published Terms explicitly state that approval is not guaranteed